Skip to main content

Table 1 Patients background in high and low initial CBZ dose groups

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

Factors Total (n = 118) High (n = 37) Low (n = 81) P (High vs Low)
Median age at diagnosis (y) 65 (47–81) 65 (47–76) 66 (49–81) 0.087
Median PSA at diagnosis (ng/mL) 61.0 (5.0–21,114) 61.2 (3.2–21,114) 61.0 (5.0–9430) 0.840
GS at diagnosis≥9 70 (61%) 25 (68%) 45 (55%) 0.290
Metastatic status at diagnosis No: 34 (29%) No: 11 (30%) No: 23 (28%) 0.528
LN:15 (13%) LN:5 (14%) LN:10 (12%)
Bone< 6:37 (31%) Bone< 6:8 (22%) Bone< 6:29 (36%)
Bone> 5:24 (20%) Bone> 5:10 (27%) Bone> 5:14 (17%)
Visceral:8 (7%) Visceral:3 (8%) Visceral:5 (6%)
Median age at CBZ start (y) 70 (48–88) 70 (48–79) 72 (50–88) 0.182
Median PSA at CBZ start (ng/ml) 75.2 (0.07–9586) 52.3 (3.44–1610) 78.0 (0.07–9586) 0.550
PS at CBZ start≥1 62 (53%) 13 (35%) 49 (60%) 0.017*
Median RDI of CBZ 60% (30–100%) 75% (60–100%) 60% (30–80%) < 0.001*
  1. PS performance status, RDI relative dose intensity *P < 0.05